We used 2006-2015 US National Assisted Reproductive Technology Surveillance System data to compare preterm birth and fetal growth for liveborn singletons (24-42 weeks' gestation) following in vitro fertilization with donor versus autologous oocytes. Using binary and multinomial logistic regression, we computed adjusted odds ratios and 95% confidence intervals for associations between use of donor oocytes and preterm delivery, being small for gestational age (SGA), and being large for gestational age (LGA), stratified by fresh and thawed embryo status and accounting for maternal characteristics and year of birth. There were 204,855 singleton births from fresh embryo transfers and 106,077 from thawed embryo transfers. Among fresh embryo transfers, donor oocyte births had higher odds of being preterm (adjusted odd ratio (aOR) = 1.32, 95% confidence interval (CI): 1.27, 1.38) or LGA (aOR = 1.27, 95% CI: 1.21, 1.33) but lower odds of being SGA (aOR = 0.81, 95% CI: 0.77, 0.85). Among thawed embryo transfers, donor oocyte births had higher odds of being preterm (aOR = 1.57, 95% CI: 1.48, 1.65) or SGA (aOR = 1.22, 95% CI: 1.14, 1.31) but lower odds of being LGA (aOR = 0.87, 95% CI: 0.82, 0.92). Use of donor oocytes was associated with increased odds of preterm delivery irrespective of embryo status; odds of being SGA were increased for donor versus autologous oocyte births among thawed embryo transfers only. assisted reproduction; donor egg; in vitro fertilization; perinatal outcomes; preterm; small for gestational age Abbreviations: AGA, appropriate for gestational-age; aOR, adjusted odds ratio; ART, assisted reproductive technology; CI, confidence interval; LGA, large for gestational age; IVF, in vitro fertilization; SGA, small for gestational age.
In the United States, use of donor oocytes for in vitro fertilization (IVF) procedures has increased over time largely due to delayed childbearing and the concomitant decline in the number and quality of eggs with advancing female age (1) . In 2014, donor oocyte cycles accounted for over 9% of all assisted reproductive technology cycles and resulted in over 8,500 live births (2) . The literature on the association between donor oocyte cycles and adverse perinatal outcomes is equivocal; results from some but not all studies suggest higher rates of obstetrical complications such as first-trimester vaginal bleeding (3, 4) , hypertensive disorders of pregnancy (5) (6) (7) (8) (9) (10) (11) (12) , induction of labor (13) , cesarean delivery (5, 8, 10, 12, 13) , and postpartum hemorrhage (5, 10) for IVF conceptions from donor oocytes compared with autologous oocytes. Likewise, use of donor oocytes has been variably associated with increased risk for low birth weight (5, 6, 10, 12, (14) (15) (16) and preterm delivery (5, 6, 8, 10, 12, (14) (15) (16) ) when compared with births from IVF using autologous oocytes, even when restricted to singletons. Although there is some evidence of higher proportions of births from donor versus autologous oocytes being small for gestational age (SGA, <10th percentile of birth weight for gestational age), the associations tend to be smaller in magnitude and lack statistical significance (5, 6, 10, 12, 17) .
Studies of the potential associations between use of donor oocytes and infant outcomes may be complicated by the frequent use of frozen-thawed embryos in donor cycles. In 2014, 58% of donor cycles used frozen-thawed embryos compared with 38% of autologous cycles (2) . Infants born following thawed autologous embryo transfer have been found to have higher average birth weights and lower odds of preterm and SGA birth compared with those conceived following a fresh embryo transfer (18) (19) (20) (21) ; however, none of these studies compared infant outcomes for births from donor and autologous oocytes stratified by embryo status (fresh versus frozen-thawed embryo transfer). The aim of this study was to examine patterns of preterm birth and being SGA for singleton births resulting from donor oocyte IVF versus autologous oocyte IVF and to explore the role of embryo status as a potential effect measure modifier. We hypothesized that donor oocyte infants would have higher rates of preterm birth and growth restriction than autologous oocyte infants but that the associations would be attenuated for frozen-thawed cycles, given prior report of improved perinatal outcomes following frozen-thawed transfer.
METHODS

Study cohort
The data used for this study were derived from the Center for Disease Control and Prevention's National Assisted Reproductive Technology Surveillance System (NASS), which collects information on nearly all (98%) assisted reproductive technology (ART) cycles performed in US fertility clinics, as mandated by the Fertility Clinic Success Rates and Certification Act (22) . Since 1995, NASS has collected data on patient demographic factors, obstetrical and medical history, ART treatment procedures, and resultant pregnancies and births. Each year, a random sample of fertility clinics that submitted data to NASS is selected for data validation, in which trained abstractors visit the clinics and compare data reported to NASS with medical records. Discrepancy rates were <5.6% for all fields evaluated in 2015 (23) .
We included all IVF cycles performed between 2006 and 2015 that resulted in a singleton gestation (1 fetal heart observed on ultrasound prior to 7 weeks' gestation) and a liveborn singleton infant (n = 333,113). We excluded cycles using donated embryos (n = 2,837), cryopreserved eggs (n = 2,833, only reported for fresh embryo transfers from 2013 onward), or a gestational carrier (n = 8,215). Infants with gestational ages <24 weeks and >42 weeks (n = 7,798) and those with implausible birth weight and gestational age combinations (n = 498) (24) were also excluded. The study was approved by the institutional review board of the Centers for Disease Control and Prevention.
Assessment of exposure
Information on type of oocytes and embryos was ascertained from clinic-reported data on oocyte source and embryo state (autologous oocyte with a fresh embryo transfer, donor oocyte with a fresh embryo transfer, autologous oocyte with thawed embryo transfer, donor oocyte with thawed embryo transfer).
Assessment of outcomes
For fresh embryo transfers with information on date of oocyte retrieval, gestational week was calculated as: (date of delivery − date of oocyte retrieval + 14 days)/7. When date of oocyte retrieval was missing, gestational week was calculated as (date of delivery − date of embryo transfer + 17 days)/7 and assumed that the average time in embryo culture was 3 days during the study period. Information on infant birth weight was collected by clinics and was based on clinician or patient report. Using gestational age and birth weight information, we classified births as preterm (<37 weeks of gestation), SGA (<10th percentile of birth weight for gestational age), appropriate for gestational age (AGA; 10th-90th percentile of birth weight for gestational age), or large for gestational age (LGA; >90th percentile of birth weight for gestational age). In addition, we further categorized SGA, AGA, and LGA births according to preterm and term (37-42 weeks) delivery.
Assessment of patient and treatment characteristics
The patient and treatment characteristics included in the study were reported by clinics as part of routine ART surveillance. They included female patient age at cycle start, age of oocyte source at retrieval, race/ethnicity, prepregnancy body mass index, parity, previous preterm birth, reason for ART, number of prior ART cycles, number of oocytes retrieved, oocyte donor age at retrieval, embryo stage at transfer, number of embryos transferred, number of embryos cryopreserved, use of assisted hatching, use of intracytoplasmic sperm injection, and use of donor sperm.
Statistical analyses
We examined the distribution of patient and treatment characteristics for singleton births from donor and autologous oocytes, stratified by use of a fresh or thawed embryo transfer. χ 2 tests were used to test for differences in distributions of characteristics for births from donor versus autologous oocytes.
We calculated the 10th, 50th, and 90th percentiles of birth weight for gestational age for singleton births according to oocyte source (autologous or donor) and embryo status (fresh or thawed) for all births and stratified by male and female sex. Cubic splines were used to smooth gestational age-specific birth weight values.
Finally, we used binary and multinomial logistic regression models to compute unadjusted and adjusted odds ratios and 95% confidence intervals for associations between use of donor oocytes and preterm delivery (binary) and fetal growth categorized as a 3-level (SGA, AGA, and LGA) or 6-level (SGA preterm, SGA term, AGA preterm, AGA term, LGA preterm, and LGA term) outcome. The birth weight-gestational age thresholds (SGA, AGA, and LGA) accounted for infant sex. The interaction of use of donor oocytes and embryo status (fresh or thawed) was included in the models, and stratified results are reported.
Covariates for the adjusted model were selected a priori and included female patient age, infertility diagnosis (tubal factor, history of endometriosis, uterine factor, ovulatory disorder, diminished ovarian reserve, male factor infertility, and unexplained infertility), parity, number of prior ART cycles, and year of cycle start. To account for variation in use of donor oocytes among clinics, we used a hybrid fixed-effects approach with cluster mean values for proportion of donor cycles included as a fixed effect and clinic included as a random effect (25) . This approach accounts for clinic-level variation in the outcome and the exposure and adjusts the other covariates for clinic-level differences related to use of donor oocytes (25) .
Because women using donor oocytes tend to be older and because advanced maternal age is associated with increased risk for adverse perinatal outcomes, we conducted a sensitivity analysis limiting the study population to births to women <40 years of age. Also, because we were unable to include body mass index in the models due to a high proportion of missing values (>40%), we included an additional sensitivity analysis restricted to records with information on body mass index.
Analyses were conducted using SAS, version 9.4 (SAS Institute, Inc., Cary, North Carolina). P values of <0.05 were considered statistically significant.
RESULTS
After exclusions, the final sample included 310,932 singleton births at 24-42 weeks' gestation that resulted from IVF cycles initiated between 2006 and 2015. Of those, 57.5% (n = 178,654) were conceived using fresh embryos with autologous oocytes, 8.4% (n = 26,201) used fresh embryos with donor oocytes, 29.1% (n = 90,494) used thawed embryos with autologous oocytes, and 5.0% (n = 15,583) used thawed embryos with donor oocytes. Regardless of embryo status, women who used donor oocytes tended to be older, had a history of 2 or more prior ART cycles, and were more frequently diagnosed with diminished ovarian reserve than women using autologous oocytes. (Table 1 ) Among births from fresh embryo transfers, the proportion of births following the transfer of 2 or more embryos was lower for those using donor versus autologous oocytes (8.0% versus 23.3%, respectively); similarly, the proportion of births where assisted hatching was used was lower for donor oocyte births (18.6% versus 34.3%, respectively). Figure 1 depicts the 10th, 50th and 90th percentiles of birth weight according to gestational age after smoothing for all singleton IVF births from autologous and donor oocyte embryos, stratified by embryo status. Among fresh embryo transfers, the 10th-percentile values between 25 and 41 weeks were higher for donor oocyte births compared with those using autologous oocytes ( Figure 1A ), although differences were minimal (<5%) at gestational ages beyond 32 weeks. Likewise, gestational age-specific birth weights at the 90th percentile were slightly higher for donor oocyte births than autologous oocyte births from 25 weeks onward. In contrast, among thawed embryo transfers, the 10th-percentile values for donor oocyte births were lower than autologous oocyte births for nearly every gestational age, and the 90th-percentile values were lower after 27 weeks' gestation ( Figure 1B ). Similar trends were observed using sex-specific growth curves. (Web Figures 1  and 2 , available at https://academic.oup.com/aje).
P values for the interaction of the use of donor oocytes and embryo status were <0.0001 for all models with the exception of preterm birth in the sensitivity analysis restricted to women <40 years of age. Among fresh embryo transfers, use of a donor oocyte was associated with increased odds of preterm birth (adjusted odd ratio (aOR) = 1.32, 95% confidence interval (CI): 1.27, 1.38). (Table 2 ) Donor oocyte births also had decreased odds of being SGA compared with autologous oocyte births (aOR = 0.81, 95% CI: 0.77, 0.85) but increased odds of being LGA (aOR = 1.30, 95% CI: 1.23, 1.37). When fetal growth was further classified according to preterm and term birth, use of donor oocytes was associated with reduced odds of SGA term birth (aOR = 0.83, 95% CI: 0.79, 0.88) but not SGA preterm birth (aOR = 1.01, 95% CI: 0.89, 1.15). In addition, odds of being AGA and preterm, LGA and preterm, or LGA and term were all higher for donor versus autologous oocyte births.
Among thawed embryo transfers, use of a donor oocyte was also associated with increased odds of preterm birth (aOR = 1.57, 95% CI: 1.48, 1.65). However, in contrast with fresh embryo transfers, donor oocyte births following a thawed embryo transfer had increased odds of being SGA (aOR = 1.22, 95% CI: 1.14, 1.31) and decreased odds of being LGA (aOR = 0.87, 95% CI: 0.82, 0.92) compared with autologous oocyte births. Furthermore, odds of SGA preterm (aOR = 1.89, 95% CI: 1.60, 2.24), SGA term (aOR = 1.26, 95% CI: 1.16, 1.36), AGA preterm (aOR = 1.61, 95% CI: 1.52, 1.71), and LGA preterm (aOR = 1.24, 95% CI: 1.07, 1.43) births were higher for donor versus autologous oocyte births, while odds of LGA term birth were lower (aOR = 0.89, 95% CI: 0.83, 0.95).
Observed associations for women <40 years of age were similar to those for the entire population (Web Table 1 ), as were estimates when maternal body mass index was included as a covariate (Web Table 2 ).
DISCUSSION
Our results suggest that use of donor versus autologous oocytes was associated with increased odds of preterm birth for singleton births conceived using either fresh or thawed embryos. However, embryo status modified the association between use of donor oocytes and fetal growth. For example, whereas donor oocyte births from fresh embryo transfers had a lower rate of SGA birth than autologous oocyte births, donor oocyte births from thawed embryo transfers had a higher rate of being SGA compared with autologous oocyte births. In addition, when fetal growth outcomes for singleton births from fresh embryo transfers were further classified by length of gestation, donor oocyte births were less likely than autologous oocyte births to be SGA and term but more likely to be AGA and preterm, LGA and preterm, or LGA and term. In contrast, among thawed embryo transfers, use of donor oocytes was associated with nearly 2-fold higher odds of being SGA and preterm but was protective for LGA term birth.
Our finding, that use of donor oocytes was associated with an increased overall risk for preterm birth irrespective of embryo status, is consistent with several other studies (10, 12, 14) . It has been suggested that the association between use of donor oocytes and adverse perinatal outcomes such as preterm birth and hypertensive disorders of pregnancy may be due to abnormal placental development caused by maternal immune response to fetal antigens from a donor oocyte pregnancy (12, 26) . Given that women using donor oocytes tend to be older or have a history of prior failed IVF cycles (1), unmeasured factors related to advanced maternal age, nulliparity, and premature ovarian insufficiency may also contribute to elevated risks for adverse perinatal outcomes (13, 27) .
Increases in LGA incidence after cryopreservation of embryos have also been also observed previously, particularly for autologous oocytes, for which the odds of being SGA decrease from fresh to thawed while the odds of being LGA increase (20, 21, 28) . This may be due to either a treatment effect on the growth axis of autologous embryos or a reduction in the survivorship of autologous embryos with the propensity to be SGA. Of the few studies that compared rates of SGA birth for donor versus autologous oocyte births, most suggest little or no association (5, 6, 10, 11). However, unlike the present study, prior investigations typically combined fresh and thawed embryos, which may have contributed to biased estimates. Our results suggest that associations between use of donor oocytes and SGA birth differ by embryo status, a finding that has not, to our knowledge, been previously reported. The mechanism for this association is not known. It has been hypothesized that the supraphysiologic doses of gonadotropins used during controlled ovarian stimulation may negatively affect endometrial receptivity, resulting in the lower rates of implantation, clinical pregnancy, and live birth that have been reported for fresh, autologous transfers, as compared with cycles in which no ovarian stimulation is performed (both frozen autologous embryo transfers (19, 28) and fresh donor embryo transfers (29) ). This etiology may explain our finding of lower rates of SGA birth in donor-oocyte births following fresh embryo transfer. However, in thawed embryo transfers, the uterine environment is ostensibly similar for pregnancies conceived using donor and autologous oocytes because ovarian stimulation was not performed. The increased rate of being SGA for donor oocyte births among thawed embryo transfers observed in our study might thus be more representative of the maternal response to donor oocytes, because the competing risks resulting from ovarian stimulation are absent. In other words, it is possible that the uterine environment had a greater influence on growth restriction in fresh embryo transfer cycles than did the use of donor oocytes.
The primary strength of our study is the use of a national database with detailed, high-quality information on ART procedures and sufficient sample size to assess both preterm and SGA births among donor oocyte births following fresh and thawed embryo transfer. Also, by limiting our analysis to singleton infants from single-gestation pregnancies, we were able to reduce the potential impact of confounding due a vanishing twin on perinatal outcomes. However, our findings are subject to several limitations. First, we were unable to assess the frequency of pregnancy complications, most notably hypertensive disorders of pregnancy. Although these factors likely fall on the causal pathway, information on their co-occurrence with preterm and SGA birth would provide important evidence on potential etiology of the outcomes studied in this analysis, especially given the potential for common biological mechanisms related to maternal immune response and placental pathology (26, 30) . In addition, we were unable to distinguish between iatrogenic and spontaneous preterm birth and could not evaluate growth restriction among fetal deaths or for infants born before 24 weeks' gestation. Furthermore, the measures of fetal growth used in this study represent the outcomes of infants born at a particular gestational age, whereas valid assessments of fetal growth require serial measurements over the course of pregnancy. Finally, unmeasured confounding may have affected our estimates. LGA, large for gestational age; OR, odds ratio; SGA, small for gestational age. a Adjusted for patient age, infertility diagnosis (tubal factor, history of endometriosis, uterine factor, ovulatory disorder, diminished ovarian reserve, male infertility, unexplained infertility), parity, number of prior cycles of assisted reproductive technology, and year of cycle. Models also incorporated a hybrid fixed-effects approach with clusters (clinic) included as random effects and cluster means of the percentage of donor cycles included as a fixed effect. In conclusion, we found that the use of donor oocytes was associated with increased odds of preterm delivery among singleton births conceived using both fresh and thawed embryo transfer. In addition, rates of being SGA were higher for donor oocyte births than for autologous oocyte births but only among thawed embryo transfers, suggesting that changes in the uterine environment associated with controlled ovarian stimulation may have a greater influence on perinatal outcomes in the context of fresh embryo transfer. More research is needed to better understand the pathologies that may underlie maternal and fetal complications of donor oocyte pregnancies as well as the potential for adverse long-term outcomes.
